Nine early career scientists named 2019 recipients of the Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that nine scientists with novel approaches to fighting cancer have been named 2019 recipients of the Damon Runyon-Rachleff Innovation Award. Initial grants of $400,000 over two years were awarded to five early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer. Each awardee will have the opportunity for up to two additional years of funding (four years total for $800,000). In addition, continued "Stage 2" support was granted to four awardees, who demonstrated significant progress on their proposed research during the first two years of the award. This year, the Foundation increased the award by 33% from $150,000 to $200,000 annually.

The Damon Runyon-Rachleff Innovation Award funds cancer research by exceptionally creative thinkers with "high-risk/high-reward" ideas who lack sufficient preliminary data to obtain traditional funding. The awardees are selected through a highly competitive and rigorous process by a scientific committee comprised of leading cancer researchers who are innovators themselves. Only those scientists with a clear vision and passion for cancer research are selected to receive the prestigious award. Examples of past success stories from Damon Runyon awardees include the gene editing technology CRISPR and single cell sequencing techniques that are revolutionizing not just cancer research, but biomedical research globally.

This program was established thanks to the generosity of Andy and Debbie Rachleff.

2019 Damon Runyon-Rachleff Innovators:

Xiaochun Li, PhD
The University of Texas Southwestern Medical Center

Dr. Li is focusing on the Hedgehog (Hh) signaling pathway, which is required for proper development during the formation of an embryo. This pathway can also be activated abnormally in adult tissue and has been implicated in multiple cancers--including basal cell carcinoma and medulloblastoma--that account for about 25% of cancer deaths. His lab will apply structural and cell biological approaches to study two major components of the Hedgehog signaling pathway: Patched-I, a tumor suppressor, and Smoothened, an oncoprotein. These results will broaden the understanding of the Hh pathway in cancer progression and may help identify potential targets for therapeutic intervention.

Joseph D. Mancias, MD, PhD
Dana-Farber Cancer Institute

Dr. Mancias is exploring the synergistic interactions between radiation therapy and targeted immunotherapy in patients with pancreatic cancer (pancreatic ductal adenocarcinoma, "PDAC"). While this treatment combination has shown dramatic benefits for patients with certain cancer types, it has been challenging to predict which patients will respond and to determine how to harness the anti-tumor immune cell effects of radiation. Identifying the PDAC radiation-induced antigens will shed light on the interaction between the immune system and radiation and provide the basis for designing effective immunotherapies for patients with pancreatic and other cancers (such as glioblastoma, prostate cancer, breast cancer, lung cancer, head and neck cancers, pediatric cancers).

Jan P. Schuemann, PhD
Massachusetts General Hospital

Though radiation therapy is a key treatment for many solid tumors, healthy surrounding tissue can be damaged through inadvertent exposure leading to serious side effects. Dr. Schuemann's research is exploring if "extreme dose rate (EDR) proton therapy" can be used to spare healthy tissue while treating solid tumors. With new EDR technology, proton radiation therapy is delivered extremely fast--whole treatments in milliseconds. However, the mechanism underlying the reduction in side effects is still unknown. This research will focus on brain irradiations but has the potential to be applied to nearly all cancer types. These results may demonstrate how EDR treatments can greatly improve radiation therapy outcome.

Jason M. Sheltzer, PhD
Cold Spring Harbor Laboratory

Dr. Sheltzer studies how aneuploidy, or having too many or too few chromosomes in the cell, affects cancer development and treatment. Approximately 55% of breast cancers have an extra copy of one part (called the "q arm") of chromosome 1. His lab is developing cutting-edge chromosome engineering technology to eliminate the extra copies of 1q from breast cancer cell lines and determine whether this prevents the cells from forming tumors. Additionally, his group will test whether aneuploidy causes ovarian cancer cells to be sensitive to any chemotherapies, with the goal of identifying a drug that specifically kills cells with extra copies of chromosome 1q without affecting normal cells. These experiments could lead to highly effective "chromosome-specific" therapies based on aneuploidy.

Alexandra-Chloé Villani, PhD
Massachusetts General Hospital

Immune checkpoint inhibitors unleash the immune system to attack tumors; they have revolutionized the treatment of solid cancers by changing the prognosis for many patients, improving their quality of life and offering long-lasting remission. However, these immunotherapies can also spur assaults on healthy organs called "immune-related adverse events" (irAEs), ranging from minor rashes and fevers to severe gastrointestinal complications and deadly heart inflammation. Dr. Villani is analyzing patient samples using state-of-the-art genomic technologies and integrative immunological approaches to understand why and how these irAEs occur in cancer patients. Ultimately, she aims to identify therapeutic solutions to prevent or clinically manage irAEs without reducing the lifesaving potential of immunotherapy.

2019 Stage 2 Damon Runyon-Rachleff Innovators:

Benjamin L. Martin, PhD and David S. Matus, PhD
Stony Brook University

Metastasis, when tumor cells spread to distant organs and form secondary tumors, is one of the most deadly aspects of cancer but is not well understood. Drs. Martin and Matus are focusing on this process to understand how cancer cells break free from tumors to move through the body. Their collaborative project is founded upon an experimental observation made by Dr. Matus in the model roundworm, C. elegans, that a cell cannot simultaneously invade and divide. Using two model systems, C. elegans and the zebrafish, D. rerio, they have gained a better mechanistic understanding of how cell cycle arrest increases the invasive capacity of individual cells during metastasis, including extravasation, the ability to exit blood vessels into the surrounding tissue. They have developed a biosensor that allows the quantification of cells at different stages of the cell cycle and specialized light sheet microscopes to visualize invasive cancer cell behavior at high resolution, in real time. Insights from their work may aid in the design of therapeutics to eradicate metastatic cells that escape traditional chemotherapeutic agents which only target actively dividing cells.

Rushika M. Perera, PhD
University of California, San Francisco

Cancer cells have a unique ability to rapidly and efficiently remodel their internal composition and metabolic pathways in order to maintain accelerated growth, metastasize and resist anti-cancer therapies. The lysosome, an organelle in the cell that degrades cellular debris, has the ability to control a cancer cell's adaptability. Through processing and recycling different macromolecules, the lysosome serves as an important source of fuel for cancer cell growth and spare parts for remodeling the cell. Dr. Perera is focusing on pancreatic ductal adenocarcinoma (PDAC), which is highly dependent on lysosomes for growth. She has characterized cancer-specific lysosomal proteins and showed that these proteins confer PDAC cells with two key properties: the ability to rapidly repair their membranes in the face of sustained mechanical and chemical insults, in order to maximize nutrient uptake, and to alter their cell membrane composition to evade recognition by the host immune system. Collectively, these results suggest largely unexplored roles for the lysosome in PDAC and highlight novel vulnerabilities that could be exploited therapeutically.

Marcela V. Maus, MD, PhD
Massachusetts General Hospital

Dr. Maus is engineering the body's own immune T cells to fight deadly brain tumors like glioblastoma. However, in studies of patients with brain tumors, she has found that tumor cells can escape the engineered T cells. She is now redesigning T cells so that they block escape routes used by the tumors. She expects that the engineered cells will be more powerful and may become a new effective treatment for brain tumors. The engineered CAR T cells are designed to target cells displaying multiple abnormal proteins (antigens) made from cancer-causing oncogenes; theywill act as drug carriers to address the specific hurdles of antigen heterogeneity and penetrating the blood brain barrier. She is testing these "living drugs" in vitro and in mouse models with the goal of ultimately advancing these studies to human clinical trials. Furthermore, if this system works for brain tumors, it has the potential to be applied as a therapy for other forms of cancer as well.

DAMON RUNYON CANCER RESEARCH FOUNDATION

To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today's best young scientists with funding to pursue innovative research. The Foundation has gained worldwide prominence in cancer research by identifying outstanding researchers and physician-scientists. Twelve scientists supported by the Foundation have received the Nobel Prize, and others are heads of cancer centers and leaders of renowned research programs. Each of its award programs is extremely competitive, with less than 10% of applications funded. Since its founding in 1946, the Foundation has invested over $360 million and funded over 3,700 young scientists. This year, it will commit approximately $19 million in new awards to brilliant young investigators.

100% of all donations to the Foundation are used to support scientific research. Its administrative and fundraising costs are paid from its Damon Runyon Broadway Tickets Service and endowment.